3300 Bee Cave Road, #650-227
Austin, TX 78746
June 7, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jason Drory
Re: | Genprex, Inc. |
| Registration Statement on Form S-3 |
| Filed on April 21, 2023 | |
| File No. 333-271386 |
| Acceleration Request | |
| Requested Date: June 9, 2023 | |
| Requested Time: 4:30 p.m., Eastern Time |
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement (the "Registration Statement"), and pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Genprex, Inc. (the "Company") hereby requests that the above-mentioned Registration Statement be declared effective by the Securities and Exchange Commission (the "Commission") at 4:30 p.m., Eastern Time, on June 9, 2023, or as soon thereafter as practicable.
Please call Alan Wovsaniker of Lowenstein Sandler LLP at 973-597-2564 to confirm the effectiveness of the Registration Statement or with any questions that you may have.
| GENPREX, INC. | |
|
| |
| By: | /s/ Ryan M. Confer |
| Name: | Ryan M. Confer |
| Title: | Chief Financial Officer |